Cynapsus Therapeutics Parkinson’s Disease Candidate Gets FDA Fast Track Designation


(August 31, 2016) - Cynapsus Therapeutics said its APL-130277 product candidate for the treatment of off-episodes in patients with Parkinson’s Disease has received fast track designation from the U.S. Food and Drug Administration (FDA). The company said its phase 3 clinical program for the treatment is nearing completion and that it plans to submit a new drug application to the FDA in the first half of 2017. Read more…

Click for a printer friendly version

Back to top